Table 2.
PFS and OS in relation to tumor localization in the two treatment groups (CT + B and CT).
| PFS | OS | ||||||
|---|---|---|---|---|---|---|---|
| No. Patients | No. Events | Median PFS (months) (95% CI) | p | No. Events | Median OS (months) (95% CI) | p | |
| Overall | |||||||
| CT + B | 60 | 53 | 9.6 (8.3–12.4) | 49 | 21.4 (14.4–28.8) | ||
| CT | 62 | 56 | 9.1 (8.3–10.0) | 0.435 | 49 | 23.2 (18.2–28.0) | 0.601 |
| Right-sided | |||||||
| CT + B | 26 | 23 | 12.6 (8.6–16.0) | 21 | 27.5 (15.9–35.7) | ||
| CT | 25 | 24 | 9.0 (6.5–10.3) | 0.017 | 20 | 20.4 (13.8–26.4) | 0.380 |
| Left-sided | |||||||
| CT + B | 34 | 30 | 9.1 (6.8–10.9) | 28 | 19.7 (12.7–27.1) | ||
| CT | 37 | 32 | 9.1 (7.2–13.0) | 0.458 | 29 | 27.1 (18.2–36.6) | 0.194 |
PFS, progression-free survival; OS, overall survival; CT, chemotherapy; B, bevacizumab.